Literature DB >> 2495831

Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.

S Dauvois1, F Labrie.   

Abstract

The effect of the adrenal steroids androst-5-ene-3 beta,17 beta-diol (delta 5-diol) and androstenedione (delta 4-dione) was studied on the growth of mammary carcinoma induced in the rat by dimethylbenz[a]anthracene (DMBA). The plasma levels of the two steroids were maintained at values within the range of those found in the circulation of post-menopausal women by constant release from osmotic pumps in ovariectomized animals. delta 5-diol and delta 4-dione, at the daily release rate of 500 micrograms, led to plasma levels of 1.26 +/- 0.19 and 1.72 +/- 0.75 ng/ml, respectively. At these physiologically relevant plasma concentrations, both delta 5-diol and delta 4-dione caused a marked stimulation of tumor growth while having minimal or no effect on uterine weight or on plasma prolactin and LH levels. Concomitant treatment with the aromatase inhibitor aminoglutethimide completely blocked the stimulatory effect of delta 4-dione released from silastic implants on tumor growth, while simultaneous administration of the antiandrogen flutamide had no significant effect. On the other hand, when aminoglutethimide was administered with delta 5-diol, the stimulatory effect of the adrenal steroid on tumor growth was not affected. Such data indicate that, under the present experimental conditions, transformation of delta 4-dione into androgens plays a minor role, the predominant effect of the adrenal steroid being stimulation of tumor growth through conversion into estrogens, while delta 5-diol exerts a direct estrogenic effect independent from aromatase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495831     DOI: 10.1007/bf01806551

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  36 in total

1.  Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat.

Authors:  J Asselin; F Labrie
Journal:  J Steroid Biochem       Date:  1978-11       Impact factor: 4.292

2.  Dehydroepiandrosterone: kinetics of metabolism in normal men and women.

Authors:  C E Bird; J Murphy; K Boroomand; W Finnis; D Dressel; A F Clark
Journal:  J Clin Endocrinol Metab       Date:  1978-10       Impact factor: 5.958

3.  Androstenediol levels in human peripheral plasma.

Authors:  R L Rosenfield; P Otto
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

Review 4.  Steroid hormone receptors in human breast cancer.

Authors:  G W Sledge; W L McGuire
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

5.  Steroid-hormone receptors in breast cancer.

Authors:  J L Wittliff
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

6.  Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor.

Authors:  J B Adams; L Archibald; K Seymour-Munn
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

7.  Products of dehydroepiandrosterone metabolism by human mammary tumors and their influence on estradiol receptor binding.

Authors:  K Li; T Foo; J B Adams
Journal:  Steroids       Date:  1978-01       Impact factor: 2.668

8.  Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue.

Authors:  A A van Landeghem; J Poortman; M Nabuurs; J H Thijssen
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Effects of 17-alpha-thioestradiol, 2 estradiol analogs, and 2 androgens on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  M N Teller; C C Stock; M Bowie
Journal:  Cancer Res       Date:  1966-11       Impact factor: 12.701

10.  Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors.

Authors:  C HUGGINS; G BRIZIARELLI; H SUTTON
Journal:  J Exp Med       Date:  1959-01-01       Impact factor: 14.307

View more
  12 in total

1.  Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.

Authors:  Matthew J Sikora; Viktoriya Strumba; Marc E Lippman; Michael D Johnson; James M Rae
Journal:  Breast Cancer Res Treat       Date:  2012-03-29       Impact factor: 4.872

2.  C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors.

Authors:  Dharshini Ganeshapillai; L W Lawrence Woo; Mark P Thomas; Atul Purohit; Barry V L Potter
Journal:  ACS Omega       Date:  2018-09-06

3.  Toxicity and carcinogenicity of androstenedione in F344/N rats and B6C3F1 mice.

Authors:  Chad R Blystone; Susan A Elmore; Kristine L Witt; David E Malarkey; Paul M D Foster
Journal:  Food Chem Toxicol       Date:  2011-05-30       Impact factor: 6.023

4.  Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat.

Authors:  S Dauvois; S M Li; C Martel; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

5.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  S Li; C Lévesque; C S Geng; X Yan; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

6.  Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  F Labrie; S Li; C Labrie; C Lévesque; Y Mérand
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

7.  Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

Authors:  Paul M Wood; L W Lawrence Woo; Mark P Thomas; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-05-23       Impact factor: 3.466

8.  Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).

Authors:  L W Lawrence Woo; Dharshini Ganeshapillai; Mark P Thomas; Oliver B Sutcliffe; Bindu Malini; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-08-25       Impact factor: 3.466

Review 9.  Steroid Sulphatase and Its Inhibitors: Past, Present, and Future.

Authors:  Paul A Foster
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

10.  Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors.

Authors:  Mohammed I El-Gamal; Mohammad H Semreen; Paul A Foster; Barry V L Potter
Journal:  Bioorg Med Chem       Date:  2016-04-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.